| Recruiting | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic O NCT05019703 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosa NCT05691478 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Recruiting | Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma NCT05235165 | Children's Oncology Group | Phase 3 |
| Completed | Indo-cyanine Green (ICG) in Paediatric Oncology MIS NCT04854018 | Birmingham Women's and Children's NHS Foundation Trust | Phase 4 |
| Active Not Recruiting | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma NCT04668300 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma NCT02484443 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma NCT02470091 | Children's Oncology Group | Phase 2 |
| Completed | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone NCT02357810 | Northwestern University | Phase 2 |
| Active Not Recruiting | Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma NCT02243605 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma NCT01886105 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Terminated | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung NCT01759303 | Emerald Clinical Inc. | Phase 2 |
| Active Not Recruiting | Aerosolized Aldesleukin in Treating Patients With Lung Metastases NCT01590069 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma NCT01374672 | Children's Oncology Group | — |
| Completed | Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarc NCT01804374 | Italian Sarcoma Group | Phase 2 |
| Completed | DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma NCT01190943 | Children's Oncology Group | — |
| Completed | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced NCT01154452 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue NCT01016015 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas NCT01807052 | Children's Oncology Group | — |
| Completed | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery NCT01553539 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Study of Blood Samples From Patients With Osteosarcoma NCT00954473 | Children's Oncology Group | — |
| Completed | Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) NCT00330421 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma NCT00134030 | Children's Oncology Group | Phase 3 |
| Completed | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors NCT00093821 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma NCT00023998 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241 | National Cancer Institute (NCI) | Phase 1 |